CIRM Funded Clinical Trials

Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma

Disease Area: 
Investigator:
CIRM Grant:
CLIN2-12595 (Pre-Active)
Award Value:
$11,998,310
Trial Sponsor:
Stanford University
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
54
ClinicalTrials.gov ID: